Article

First treatment for neuromyelitis optica spectrum disorder receives FDA approval

Intravitreal injection treats rare autoimmune disease of the central nervous system

In a press release issued by the FDA, eculizumab (Soliris, Alexion) has been approved by the U.S. Food and Drug Administration to treat neuromyelitis optica spectrum disorder (NMOSD). It is an intravitreal injection for adults who are anti-aquaporin-4 (AQP4) antibody positive. NMOSD is a rare, central nervous system disease which manifests itself in the optic nerves and spinal cord.

“Soliris provides the first FDA-approved treatment for neuromyelitis optica spectrum disorder, a debilitating disease that profoundly impacts patients’ lives,” said Billy Dunn, MD, in a press release. Dr. Dunn is the director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research.

NMOSD causes an autoimmune reaction in which the body attacks optic and spinal cord cells. In cases of the eye, it can cause optic neuritis, a condition that often leads vision pain and loss. According to the release, nearly 50% of patients affected with NMOSD have permanent paralysis and visual loss. 

A clinical study detailing the effectiveness of eculizumab for the treatment of NMOSD was conducted with 143 patients. The patients all had NMOSD with antibodies against AQP4 (anti-AQP4 positive). Patients were randomized into placebo and eculizumab treatment groups. The results showed patients who received eculizumab treatment had a 94% reduction in NMOSD relapse over the trial period, which was 48 weeks.

Read the full announcement here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.